Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with China’s Hansoh Pharmaceuticals Group Company to acquire exclusive clinical ...

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual GLP-1/GIP receptor agonist in a deal worth $2bn. The in-licensing agreement will ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

at Regeneron, explained in the Hansoh deal release. “This is an exciting development in our obesity work at Regeneron, which also includes the muscle-sparing phase 2 COURAGE study investigating ...

The deal, announced Monday ... studies include a Phase 3 obesity trial in China and a Phase 2b diabetes study. Regeneron will make an $80 million upfront payment to Hansoh, with potential future ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Regeneron inks $80 million deal with Hansoh for Phase 3 obesity trial, with up to $1.93 billion in milestone payouts. Ready to turn the market’s comeback into steady cash flow? Grab the top 3 ...

Regeneron will pay Hansoh $80m upfront ... Regeneron is expanding its clinical-stage obesity portfolio. The deal is subject to standard closing conditions, including clearances from regulatory ...